CA2854550C - .alpha.v.beta.6 peptide ligands and their uses - Google Patents

.alpha.v.beta.6 peptide ligands and their uses Download PDF

Info

Publication number
CA2854550C
CA2854550C CA2854550A CA2854550A CA2854550C CA 2854550 C CA2854550 C CA 2854550C CA 2854550 A CA2854550 A CA 2854550A CA 2854550 A CA2854550 A CA 2854550A CA 2854550 C CA2854550 C CA 2854550C
Authority
CA
Canada
Prior art keywords
peptide
peptides
avp6
binding
helix
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CA2854550A
Other languages
English (en)
French (fr)
Other versions
CA2854550A1 (en
Inventor
Mark J. Howard
Danielle Dicara
John F. Marshall
Original Assignee
Cancer Research Technology Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cancer Research Technology Ltd filed Critical Cancer Research Technology Ltd
Publication of CA2854550A1 publication Critical patent/CA2854550A1/en
Application granted granted Critical
Publication of CA2854550C publication Critical patent/CA2854550C/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Pulmonology (AREA)
  • Dermatology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
CA2854550A 2005-10-03 2006-10-03 .alpha.v.beta.6 peptide ligands and their uses Active CA2854550C (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB0520068A GB0520068D0 (en) 2005-10-03 2005-10-03 av peptide ligand
GB0520068.8 2005-10-03
CA2624618A CA2624618C (en) 2005-10-03 2006-10-03 Av.beta.6 peptide ligands and their uses

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
CA2624618A Division CA2624618C (en) 2005-10-03 2006-10-03 Av.beta.6 peptide ligands and their uses

Publications (2)

Publication Number Publication Date
CA2854550A1 CA2854550A1 (en) 2007-04-12
CA2854550C true CA2854550C (en) 2020-04-14

Family

ID=35395162

Family Applications (2)

Application Number Title Priority Date Filing Date
CA2854550A Active CA2854550C (en) 2005-10-03 2006-10-03 .alpha.v.beta.6 peptide ligands and their uses
CA2624618A Active CA2624618C (en) 2005-10-03 2006-10-03 Av.beta.6 peptide ligands and their uses

Family Applications After (1)

Application Number Title Priority Date Filing Date
CA2624618A Active CA2624618C (en) 2005-10-03 2006-10-03 Av.beta.6 peptide ligands and their uses

Country Status (7)

Country Link
US (3) US8383593B2 (https=)
EP (1) EP1957522B1 (https=)
JP (1) JP5449774B2 (https=)
CA (2) CA2854550C (https=)
ES (1) ES2638439T3 (https=)
GB (1) GB0520068D0 (https=)
WO (1) WO2007039728A2 (https=)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0520068D0 (en) 2005-10-03 2005-11-09 Cancer Res Technology av peptide ligand
EP2064244B1 (en) 2006-08-03 2019-06-05 MedImmune Limited ANTIBODIES DIRECTED TO alphaVbeta6 AND USES THEREOF
GB0718843D0 (en) 2007-09-26 2007-11-07 Cancer Rec Tech Ltd Materials and methods relating to modifying the binding of antibodies
AU2011217848B8 (en) * 2010-02-18 2015-09-24 The Regents Of The University Of California Integrin aVB8 neutralizing antibody
WO2013025261A2 (en) * 2011-04-06 2013-02-21 Georgia Tech Research Corporation Fluorogenic peptide probes and assays
WO2013078250A2 (en) * 2011-11-22 2013-05-30 The Board Of Trustees Of The Leland Stanford Junior University Cystine knot peptides that bind alpha-v-beta-6 integrin
WO2013110120A1 (en) 2012-01-24 2013-08-01 Inter-K Pty Limited Peptide agents for cancer therapy
US20140223514A1 (en) * 2013-02-01 2014-08-07 Junaid Islam Network Client Software and System Validation
GB201311031D0 (en) * 2013-06-20 2013-08-07 Queen Mary & Westfield College Method
CA2945945C (en) * 2014-04-15 2023-10-03 The Regents Of The University Of California Bi-terminal pegylated integrin-binding peptides and methods of use thereof
GB201513540D0 (en) 2015-07-31 2015-09-16 King S College London Therapeutic agents
EP3468984A4 (en) 2016-06-13 2020-03-11 The Regents of the University of California ALPHA (V) BETA (6) BINDING PEPTIDES AND METHODS OF USE THEREOF
EP3471697B1 (en) * 2016-06-16 2024-09-04 The University of Liverpool Chemical composition
ES3023938T3 (en) * 2016-09-29 2025-06-03 Univ California Neutralizing antibodies to the alpha v beta 8 integrin complex for immunotherapy
SI3535397T1 (sl) 2016-11-01 2022-04-29 Arrowhead Pharmaceuticals, Inc. Ligandi alfa-V beta-6 integrina in njihove uporabe
GB201706472D0 (en) * 2017-04-24 2017-06-07 Cancer Res Tech Ltd Tumour-targeting peptide variants
WO2019089765A1 (en) 2017-11-01 2019-05-09 Arrowhead Pharmcaceuticals, Inc. Integrin ligands and uses thereof
GB201802539D0 (en) * 2018-02-16 2018-04-04 Univ College Cardiff Consultants Ltd Modified adenoviruses
WO2020051549A1 (en) * 2018-09-07 2020-03-12 The Regents Of The University Of California Alpha(v)beta(6) integrin-binding peptides and methods of use thereof
EP4048305A1 (en) * 2019-10-25 2022-08-31 University of Washington Computational design of alpha(v) beta (6) integrin binding proteins
AU2020382099A1 (en) * 2019-11-15 2022-06-23 Ospedale San Raffaele S.R.L. Chromogranin A-derived peptides and uses thereof
JP2024516096A (ja) 2021-04-08 2024-04-12 アローヘッド ファーマシューティカルズ インコーポレイテッド 終末糖化産物受容体の発現を阻害するためのＲＮＡｉ剤、その組成物、及び使用方法
US20240209034A1 (en) * 2021-04-12 2024-06-27 University Of Washington Engineering peptides for a a vb6 integrin binding and related methods of use and synthesis
CN115010949B (zh) * 2022-07-12 2024-02-13 华熙生物科技股份有限公司 促渗物、护肤品组合物以及化妆品

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8301928D0 (en) 1983-01-24 1983-02-23 Nicholson B H Process for producing polypeptides
JPS60103596A (ja) * 1983-11-11 1985-06-07 Toshiba Corp サンプル・ホ−ルド回路
AUPM411994A0 (en) * 1994-02-25 1994-03-24 Deakin Research Limited Epitopes
CZ20012212A3 (cs) * 1998-12-19 2001-09-12 Merck Patent Gmbh Peptidická sloučenina, její použití a farmaceutický prostředek, který ji obsahuje
DE19929410A1 (de) * 1999-06-26 2000-12-28 Merck Patent Gmbh Inhibitoren des Integrins avß6
DE19933173A1 (de) * 1999-07-15 2001-01-18 Merck Patent Gmbh Cyclische Peptidderivate als Inhibitoren des Integrins alpha¶v¶beta¶6¶
EP1285001A1 (en) * 2000-05-26 2003-02-26 Glaxo Group Limited Methods for identifying modulators of the interaction between lap (latency associated peptide) and integrin alpha.v.beta.3 and medical use thereof
US20030031648A1 (en) * 2000-11-28 2003-02-13 Virogene Ltd. Vectors for expressing heterologous peptides at the amino-terminus of potyvirus coat protein, methods for use thereof, plants infected with same and methods of vaccination using same
GB0520068D0 (en) 2005-10-03 2005-11-09 Cancer Res Technology av peptide ligand

Also Published As

Publication number Publication date
EP1957522A2 (en) 2008-08-20
US20090123370A1 (en) 2009-05-14
US8383593B2 (en) 2013-02-26
CA2624618A1 (en) 2007-04-12
US8927501B2 (en) 2015-01-06
WO2007039728A3 (en) 2007-09-20
US20130149248A1 (en) 2013-06-13
US9650416B2 (en) 2017-05-16
ES2638439T3 (es) 2017-10-20
CA2624618C (en) 2016-03-29
US20150125392A1 (en) 2015-05-07
WO2007039728A2 (en) 2007-04-12
JP2009509562A (ja) 2009-03-12
EP1957522B1 (en) 2017-07-12
GB0520068D0 (en) 2005-11-09
CA2854550A1 (en) 2007-04-12
JP5449774B2 (ja) 2014-03-19

Similar Documents

Publication Publication Date Title
US9650416B2 (en) αvβ6 peptide ligands and their uses
JP6906571B2 (ja) 構造化ポリペプチドの特異性のモジュレーション
CN102977191B (zh) 有效的c3补体抑制素类似物
JP2022514618A (ja) Ｐｄ－ｌ１に特異的な二環式ペプチドリガンド
JP2022518210A (ja) インテグリンαｖβ３に特異的な二環式ペプチドリガンド
CN112585157A (zh) 用于结合整联蛋白αvβ3的肽配体
JP2015534568A (ja) Ｉｒｆ５に結合する細胞透過性ペプチド
US20220090054A1 (en) Chimeric proteins
US9409961B2 (en) Cell penetrating peptides to target EIF4E
CA2632451A1 (en) Cell penetrating peptides for intracellular delivery of molecules
EP3541409B1 (en) Engineered tgf-beta monomers and their use for inhibiting tgf-beta signaling
US20220106367A1 (en) Preparation and use of ginsentides and ginsentide-like peptides
Gupta et al. De novo design of α, β‐didehydrophenylalanine containing peptides: From models to applications
JP2002512254A (ja) 新規なオメガ−コノトキシン・ぺプチド類
CN111606976A (zh) 一种小肽及其在抑制阿片成瘾性和耐受性上的应用
US20220340629A1 (en) Myosin Derived Peptides and Related Compounds with Anticoagulant Activities
CN114450399A (zh) 用于治疗癌症的乳酸脱氢酶抑制剂多肽
WO2026085280A1 (en) Cell-penetrating peptides with enhanced solubility
EP3906935A1 (en) Peptides for preventing or treating viral infections
Yu Advancing Collagen Mimicry: Covalent Triple Helix Stabilization and Higher-order Nanostructure Design
Hartgerink Advancing Collagen Mimicry: Covalent Triple Helix Stabilization and Higher-order Nanostructure Design
HIV YOUNG INVESTIGATORS ABSTRACTS
Herrera Evaluation of NMR structural studies on a family of membrane active channel forming peptides
A Guarracino Wheel of Fortune–Cyclic Peptides Hit the Mimetic Jackpot: Current Syntheses, Uses and Roles for Cyclic Peptide Mimetics
HK40015109A (en) Engineered tgf-beta monomers and their use for inhibiting tgf-beta signaling

Legal Events

Date Code Title Description
EEER Examination request

Effective date: 20140617

MPN Maintenance fee for patent paid

Free format text: FEE DESCRIPTION TEXT: MF (PATENT, 18TH ANNIV.) - STANDARD

Year of fee payment: 18

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20240923

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT DETERMINED COMPLIANT

Effective date: 20240923

Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL

Effective date: 20240923

MPN Maintenance fee for patent paid

Free format text: FEE DESCRIPTION TEXT: MF (PATENT, 19TH ANNIV.) - STANDARD

Year of fee payment: 19

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20250926

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL

Effective date: 20250926